Kornimate/medical-research-clean huggingface dataset:
the incidence and predictors of developing atrial fibrillation in patients with inferior st-segment elevation myocardial infarction after primary percutaneous coronary intervention

Conditions: Atrial Fibrillation

Summary: is to analyze the incidence and predictors of developing af in patients with inferior infarction who undergo pci with and without atrial and sn branches occlusion

atrial fibrillation (af) occurs in 5% to 18% of patient with acute st-segment elevation myocardial infarctions (stemis) and 4.5% in patients with stemi treated with percutaneous coronary intervention (pci). diagnosis of af in acute myocardial infarction (ami) patients is important because it increases the risk of cardiovascular event and associated with increased in-hospital and long term rates . atrial ischemia/infarction translates into p q segment depression or elevation on the electrocardiogram and often associates with atrial tachyarrhythmias . side-branch obstruction is one of the adverse effects of pci the location of the culprit vessel also affects the occurrence of af in ami atrial arteries arise from the right coronary artery (rca) and circumflex coronary artery (cx) and extend through the atrial myocardium to supply both chambers it is therefore conceivable that pci of lesions located at the rca and cx could lead to an accidental atrial branch occlusion . atrial myocardial ischemia secondary to atrial branches occlusion (abo) might lead to mechanical atrial dysfunction, increased electrical vulnerability to atrial arrhythmias, and late structural remodeling . the sino nodal (sn) artery originates from the proximal portion of the rca in about 60% of humans side branch occlusion of the sn artery occurring accidentally during pci for proximal rca lesions would provide an opportunity to produces sn dysfunction in humans. uptill now , there have been no systematic studies concerning sn dysfunction caused by side-branch occlusion of the sn artery during pci . left atrial volume seems to be a strong predictor of incident of af , with increase in left atrial filling pressures, atrial stretch and enlargement of the chamber occur, leading to remodeling of the structure, physiologic properties, and electrical milieu of the left atrium, culminating in the development of af

Eligibility criteria:
inclusion criteria: * patients with inferior stemi who will undergo ppci (primary percutaneous coronary intervention ) exclusion criteria: * -a history of preexisting af * prior documentation of heart failure or reduced left ventricular ejection fraction \< 50%, * severe valvular disease ( rheumatic , sclerotic ) or secondary to ami * left ventricular hypertrophy : enlargement and thickening of the walls of the ventricle * patients with inferior stemi treated with intravenous thrombolysis or conservative strategy * patients with inferior stemi who undergo primary pci and associated with right ventricular or posterior infarction * history of pulmonary embolism or copd ( chronic obstructive pulmonary disease ) * those with thyrotoxicosis

Keywords: inferior stemi
contribution of the podiatrist-posturologist in the evaluation of the link between the stabilometric parameters and the pain felt in patients with chronic low back pain

Conditions: Chronic Low Back Pain

Summary: chronic low back pain is one of the major causes of disability worldwide. knowledge about the pathophysiology of low back pain is insufficient, and an accurate diagnosis can only be obtained in 10 to 15% of cases. the absence of a precise diagnosis leads to a therapeutic challenge due to the large number of treatments available, the overall efficacy of which is low to moderate. therefore, the identification of subgroups of non-specific chronic low back pain patients is essential and will allow the optimization of therapeutic management. a detailed description of the stabilometric parameters associated with the evaluation of pain, kinematic disturbance and the degree of kinesiophobia would allow us to establish specific postural profiles, to propose a relevant clinical model and to improve the accuracy of the diagnosis of people with chronic low back pain. the objectives of this research project are to evaluate the relationship between stabilometric parameters and pain (main objective), lumbar kinematics, kinesiophobia, and quality of life (secondary objectives) in order to propose specific postural profiles in chronic low back pain patients.


Eligibility criteria:
inclusion criteria: * suffering from low back pain, possibly associated with painful gluteal radiation in the form of mono or bilateral pygalgia (non-radicular) evolving for at least three months (chronic low back pain * understanding and being able to express himself in french * giving informed, dated and signed consent exclusion criteria: * neurosurgical criteria: (i) presence of clinical signs of compression and/or single or multi-root pain (lumbosciatica with or without deficit signs, intermittent claudication of the cauda equina roots with possible sphincter signs), (ii) history inflammatory arthropathy (ankylosing spondylitis, rheumatoid arthritis), and (iii) history of lumbar spine surgery. * radiographic criteria: (i) presence on the lumbar mri of multi-level discopathy (more than 2 discopathy), (ii) spinal instability confirmed by ct or mri (degenerative spondylolisthesis or by isthmic lysis). * pregnant or breastfeeding women * visually impaired patient * patient suffering from neurological and/or orthopedic disorders that may affect balance.

Keywords: chronic low back pain kinesiophobia pain posturology stabilometry
comparison of the new fitting method cochlear nucleus fitting software (nfs) with the established fitting method cochlear nucleus custom soundtm suite (css)

Conditions: Hearing Loss

Summary: the purpose of this study is to evaluate if the new and simplified fitting method with cochlear nucleus fitting software (a major component of a suite of tools which form the clinical care innovation) provides cochlear implants recipients with the same hearing outcome as the current and established clinical fitting method with cochlear nucleus custom soundtm suite. the clinical care innovation method reduces fitting to simple volume, bass and trebles adjustments, operations which are familiar to anyone who has used an audio player.


Eligibility criteria:
inclusion criteria: * newly implanted subjects with available nucleus cochlear implants compatible with cp900 series sound processors (excluding cochlear nucleus hybrid) * post linguistically deafened adults (≥ 18 years) * unilaterally implanted * ≤ 15 years of severe to profound deafness prior to implantation * subjects who are capable and willing to participate in speech perception tests in local language * subjects who are able to provide feedback in form of a written questionnaire (e.g. speech spatial hearing qualities questionnaire) * subjects willing to give their consent to the study exclusion criteria: * additional handicaps that would prevent participation in evaluations (e.g. visual impairment, blindness) * unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure/fitting method * bilateral implantation * hybrid-l (not supported by nucleus fitting software) * subjects who already have hearing experience with a cochlear implant (e.g. reimplantation, contralateral cochlear implant) * subjects with single-sided deafness * known cochlea malformations * subjects who lost their hearing due to meningitis

Keywords: post linguistically deafness, severe to profound deafness
the effect of facilitated-tucking and shotblocker on pain caused by vaccination in healthy infants

Conditions: Procedural Pain; Pain, Acute; Nursing Caries

Summary: this study will be investigated the effects of facilitated tucking, shotblocker and combined facilitated tucking and shotblocker methods on procedural pain, crying time and duration of the procedure during hepatitis b vaccine administration in healthy term infants.

hepatitis b vaccination is one of the painful procedures routinely performed in newborns. the pain experienced by the newborn negatively affects the prognosis of the disease, the infant's behavior, the harmony with the environment, the development of the brain and senses, as well as the family-infant interaction. nonpharmacologic methods have been found to be effective in alleviating pain during interventions that cause pain caused by medical procedures that newborns frequently encounter. facilitated tucking and shotblocker are effective methods that can be used in nonpharmacologic procedural pain management. studies have commonly used parent-related methods (kangaroo care, mother/father cuddling, breastfeeding, etc.) for neonatal pain management during hepatitis b vaccine administration. in units where access to the parent is not always possible, nonpharmacologic pain methods that can be used independently of the parent can be used in the management of acute needle-related pain. in addition, no study was found in the literature comparing and combining the effect of fetal position and shotblocker application on hepatitis b vaccine-related pain. this study will be investigated the effects of facilitated tucking, shotblocker and combined facilitated tucking and shotblocker methods on procedural pain, crying time and duration of the procedure during hepatitis b vaccine administration in healthy term infants.

Eligibility criteria:
inclusion criteria: * healthy term neonates * born at 38-42 weeks gestational week, * birth weight 2500-4400 g, * 5th minute apgar score above 6, * in stable health, * able to carry out vital activities without support, * babies ordered hepatitis b vaccine by the doctor exclusion criteria: * with a genetic or congenital anomaly, * neurological, cardiological and metabolic diseases, * in need of respiratory support, * acute or chronic illness that causes pain, * a complication of childbirth, * infants of hepatitis b carrier mothers, * nerve damage or deformity in the extremity to be vaccinated, scar tissue or incision in the vastus lateralis region, * infants of mothers with a history of substance abuse

Keywords: healthy infant nonpharmacological pain management procedural pain
intradialytic exercise on the fatigue, sleep disorder, arterial stiffness and endothelial function in uremic patients

Conditions: Hemolysis; Exercise; Sleep Disorder; Fatigue; Adipocytes

Summary: to determine the effect of intradialytic cycling exercise on fatigability, sleep disorders, arterial stiffness and endothelial function in dialysis patients

the endothelium is a key regulator of vascular homeostasis and chronic exposure to vascular risk factors alters the regulatory properties of the endothelium, which progresses toward a pro-inflammatory pattern, senescence, and apoptosis. endothelial cell integrity and function are critical to the prevention of atherosclerosis, and therefore endothelial cell injury and dysfunction are major steps in the development and progression of cardiovascular disease. endothelial dysfunction may be the landmark of active disease process through the course of atherosclerotic cardiovascular disease, and a significant risk factor for future cardiovascular events. several studies had reported that not only medical treatment but also exercise could improve physical and vascular functions, dialytic efficiency, quality of sleep, fatigue and depression et al. exercise could be classified to aerobic, anaerobic exercise and resistance et. several studies have shown that regular cycling exercise in hemodialysis patients could improve physical activity, sleep quality, and reduce fatigability. therefore, exercise plays an important role in hemodialysis patients. according to these benefits, the investigator's study was designed to explore the effects of intradialytic cycling exercise on sleep quality and fatigability, adipokines and myokinins levels in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * regular hemodialysis more than 3 months with 4 hours a time, thrice a week * eligible to sign permit exclusion criteria: * could not sign permit or do not want to join the trial * infection * amputation of any one of the lower limb * hemodynamic unstable * acute myocardial infarction (ami) in recent 6 months * unstable heart condition, such as unstable angina, arrythmia * deep vein thrombosis (dvt) * history of kidney transplantation * vascular access over lower limb
a double-blind study to assess the efficacy and safety of denosumab produced by two different processes in postmenopausal women with osteoporosis

Conditions: Postmenopausal Osteoporosis

Summary: this study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.


Eligibility criteria:
inclusion criteria: * subject has provided informed consent prior to any study-specific activities/procedures * ambulatory postmenopausal women. * age 55 years or older * screening bmd value equivalent to a t-score less than or equal to -2.5 at the lumbar spine, total hip, or femoral neck. exclusion criteria: * administration of osteoporosis treatments or bone active treatments within specific timeframes * vitamin d deficiency * diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism; hypo/hyperthyroidism, unless stable and well-controlled) * contraindications to denosumab therapy (e.g., hypocalcemia)

Keywords: postmenopausal osteoporosis osteoporosis postmenopausal denosumab women
prostate cancer e-health-tutorial

Conditions: Prostate Cancer

Summary: in a participatory process involving urologists and former patients, the project team has developed an online information system ("tutorial") for patients with localized prostate cancer. in this field test, relevant outcomes are measured and the tutorial will be tested for its clinical applicability.

prostate cancer is the most common cancer in men: in switzerland, every year about 6,000 men are diagnosed with prostate cancer. men with prostate cancer at an early stage are confronted with a difficult decision: they are faced with different treatment alternatives, each with its own advantages and disadvantages. that is why a comprehensive information delivery and processing is extremely important for patients to make an informed decision. therefore, an online platform has been developed in collaboration with urologists and former patients. this online platform is designed to cover the individual information needs of patients with early prostate cancer. additionally, the software aims at facilitating cooperation between patients and doctors and at increasing the satisfaction of patients with their treatment decision. in this study, the online platform will now to be tested in clinical practice, and data will be collected for the benefit of the platform: can the online platform actually satisfy the indivudal information needs, facilitate the therapy decision and support the cooperation between doctors and patients?

Eligibility criteria:
medical inclusion criteria: * tumor stage: clinical stage t1 or t2 * psa level \<20 (psa = prostata-specific antigen) * gleason score \<8 * age ≤ 75 years * assumed life expectancy ≥ 10 years other inclusion criteria due to the study design and the type of intervention are the following: * patients have to be diagnosed in one of the trial sites * internet-enabled device in the patient's household / basal user knowledge of this device * signing of the consent form exclusion criteria: * impaired judgment * insufficient ability to read and understand german * emotional problems
kinetic study of lp(a) and pcsk9 in humans

Conditions: Cholesterol; Metabolic Disorder; Lipoproteinemia

Summary: the aim is to study the relationship between lipoprotein(a) \[lp(a)\] and pcsk9 (proprotein convertase subtilisin/kexin type 9) in humans with a kinetic study of lipoproteins in patients with dramatic increase of lp(a) and controls.

elevated plasma levels of lipoprotein(a) \[lp(a)\] are independently associated with an increased risk of cardiovascular diseases (cvd). recently an unexpected and significant 15 to 30 % reduction of lp(a) was reported with pcsk9 (proprotein convertase subtilisin/kexin type 9) inhibitors. the relation between lp(a) and pcsk9 are unclear and debated. kinetic studies of lipoprotein are an important tool to decipher the complexity of apolipoprotein metabolism in human. the comparison of apoprotein(a) and pcsk9 kinetic parameters of patients with extreme lipid disorder link to pcsk9 and apo(a) will allow to better understand the impact of pcsk9 on apo(a). from one previous in vitro study, the hypothesize is that pcsk9 increases the production rate and the assembly of lp(a). the objectives are to explore the relationship between the plasma concentration of pcsk9 and apo(a) production rate as well as the impact on the catabolic rate. patients with extreme lp(a) levels and healthy controls will be explored by performing a continuous infusion of deuterated leucine for 14 hours. lc/ms-ms will be used to analyze the samples and kinetic data of apo(a) and pcsk9 will be generated from a compartmental model. tracer enrichment analysis could be complicated for proteins with low plasma concentrations as pcsk9. this issue will be solved with spe and/or immune affinity concentration techniques. non-parametrical test and multivariate analysis will be use to describe the relationship between these two variables. this study will provide new knowledge on lp(a) and pcsk9 metabolism and their interactions in humans.

Eligibility criteria:
inclusion criteria: * age: 18 to 75 years * for subjects in the "control" group: patients with no major ldl-cholesterol deficiency (patients eligible for ldl-apheresis, eg ldl-c\> 200 mg / dl for secondary prevention and 300 mg / dl in primary prevention)) and a level of lp (a) \<50 mg / dl or * for subjects in the "high-dose" group: patients with no major ldl-cholesterol abnormalities (ldl-apheresis eligible patients, eg ldl-c\> 200 mg / dl for secondary prevention and 300 mg / dl in primary prevention)) and a level of lp (a)\> 80 mg / dl whenever possible, groups will be balanced for age, sex, familial forms of hypercholesterolemia and their major groups of mutations. exclusion criteria: * patients treated with pcsk9 antibodies. * patients with acute illness and considered incompatible by the investigator * uncontrolled diabetes (hba1c\> 8.5%) * severe hepatic insufficiency * creatinine clearance \<30 ml / min * patients not covered by a social security scheme or beneficiary of such a scheme * patients unable to understand and / or sign consent * pregnant or lactating women * minors * majors under guardianship or trusteeship or safeguard of justice
assessment of dissociative traumatic disorders

Conditions: Posttraumatic Stress Disorder

Summary: more than 70% of ambulatory patients with idd have attempted suicide (apa, 2015). this disorder, as well as all the disorders on the dissociation spectrum, must therefore be clarified and better diagnosed. the goal of this research is : 1. to assess the prevalence of dissociative disorders using specific tools in patients suffering from ptsd. 2. to validate the french version of the ddis interview (ross, 1997) that the investigators have translated.


Eligibility criteria:
inclusion criteria: * patient diagnosed with ptsd according to dsm 5 criteria * over 18 years of age * informed consent signed exclusion criteria: * neurological disorders * serious and/or unstable somatic pathologies * patient not affiliated with social security * patient hospitalized under restraint in psychiatric care by decision of the state representative or in psychiatric care at the request of a third party * patient under guardianship * patient participating in parallel in another biomedical research * change of antidepressant in the last three months * patient not mastering the french language
the evaluation of the toffee nasal pillows mask for the treatment of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this investigation is a prospective, non-randomized, non-blinded study. this investigation is designed to evaluate the performance, comfort and ease of use of the f\&p toffee nasal pillows mask amongst obstructive sleep apnea (osa) patients. up to 45 osa patients will be recruited from the ohio sleep medical institute (osmi)

visit 1 will involve the participants being consented into the trial. visit 2 will involve the participants being fitted with the f\&p toffee nasal pillows mask for use in-home. the participant will then come in to return the mask (visit three) and have a final interview, this ensures the maximum time participants will be exposed to the toffee mask in home will be 14 ± 4 days from visit two. the mask will be returned to the institution at the conclusion of the trial and the participant will return to their previous mask. the institution will recruit all patients within 1 week of the beginning of the study.

Eligibility criteria:
inclusion criteria: * adult (22+ years of age) * able to give informed consent * apnea hypopnea index (ahi) ≥ 5 on diagnostic night * either prescribed automatic positive airway pressure (apap), continuous positive airway pressure (cpap) or bi-level positive airway pressure (pap) for osa * fluent in spoken and written english * existing nasal pillows mask user exclusion criteria: * inability to give informed consent * participant intolerant to pap * anatomical or physiological conditions making pap therapy inappropriate * current diagnosis of respiratory disease or carbon dioxide (co2) retention * pregnant or may think they are pregnant.
acquired immunodeficiency syndrome(aids) and tuberculosis(tb) co-infection treatment strategies study of china.

Conditions: AIDS

Summary: to determine the best time to begin anti-hiv(acquired immunodeficiency syndrome) treatment in individuals who co-infected with hiv and tuberculosis (tb). this prospective, randomized study is being conducted on hiv/tb co-infected patients in china to evaluate and compare the efficacy of antiretroviral therapy after 2 weeks tb treatment versus deferred art initiated 8 weeks after initiation of tb treatment.

anti-tb therapy: 2hrez-4hrifb(h:isoniazid，r:rifampicin，e:ethambutol，z：pyrazinamide，rifb:rifabutin) haart: the first line was zidovudine(azt)+lamivudine(3tc)+efavirenz(efv) and the second line is stavudine(d4t)+3tc+efv study group one: after anti-tb therapy 2 weeks begin with high active antiretroviral therapy(haart); study group two: after anti-tb therapy 8 weeks begin with haart. if begin with haart and the h change with rifb.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of aids co-infected with tb cd4 t cell count lower than 350/ul must be able to swallow tablets and finish the follow-up sign the information consent form chinese exclusion criteria: * can not tolerance the therapy estimated by the doctor.

Keywords: anti- tb haart choice of the right moment